Previous 10 | Next 10 |
– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments to Reduce Cardiovascular Risk by Lowering Low-Density Lipoprotein Cholesterol (LDL-C) Level...
2024-05-20 08:33:13 ET More on Esperion Therapeutics Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript Esperion Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presen...
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment for patients with hypercholesterolemia. The trial...
2024-05-20 05:43:01 ET Summary Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue gro...
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for bempedoic acid, which is contained in NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ...
2024-05-07 10:55:22 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Esperion Therapeutics (NASDAQ: ESPR ) just reported results for the first quarter of 2024. Esperion Therapeutics reported earnings per share of 34 cents. This was above th...
2024-05-07 10:45:03 ET Rivian Automotive Inc (RIVN) RIVN is trading UP for the last 5 days, and it at trading at $10.43 with volume of 34,045,104 and a one day change of $0.10 (0.98%). Rivian Automotive Inc has a 52-week low of 12.15 and a 52-week high of $32.60. The business's 50-d...
2024-05-07 10:05:19 ET Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Conference Call May 07, 2024 08:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - President & Chief Executive Officer Ben Ha...
A look at the top 10 most actives in the United States Nuwellis Inc. (NUWE) rose 60.3% to $0.2741 on volume of 66,284,094 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 21.1% to $0.05 on volume of 64,247,106 shares Clearmind Medicine Inc. (CMND) rose 37.6% to $1.61 on volume ...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...